TXCELL Inactive Instrument
TxCell Stock CBOE EUROPE EQUITIES
Equities
0QTN
FR0010127662
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Caroline Courme
IRO | Public Communications Contact | - | 16-02-29 |
| Corporate Officer/Principal | - | - | |
Matthieu Allez
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Duncan Mckay
CHM | Chairman | - | 19-02-11 |
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection.
TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- TXCL Stock
- 0QTN Stock
